Human menstrual blood-derived stem cells reverse sorafenib resistance in hepatocellular carcinoma cells through the hyperactivation of mitophagy

BACKGROUND: Sorafenib is a first-line drug targeting the RTK-MAPK signalling pathway used to treat advanced hepatocellular carcinoma (HCC). However, tumour cells readily develop sorafenib resistance, limiting long-term therapy with this drug. In our previous study, we found that human menstrual bloo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Sining, Liu, Yiming, Zhang, Qi, Xu, Huikang, Fang, Yangxin, Chen, Xin, Fu, Jiamin, Yuan, Yin, Li, Yifei, Yuan, Li, Xiang, Charlie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068152/
https://www.ncbi.nlm.nih.gov/pubmed/37005657
http://dx.doi.org/10.1186/s13287-023-03278-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068152/
https://www.ncbi.nlm.nih.gov/pubmed/37005657
http://dx.doi.org/10.1186/s13287-023-03278-8

Ejemplares similares